Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • Enasidenib is the first FDA-approved drug that interferes with cancer cell metabolism (a hallmark of malignancy)
  • IDH enzymes are metabolic proteins that help the cell make energy from glucose and other metabolites; they can be mutated in some cancers
  • IDH2 is a mutant enzyme causing overproduction of an oncometabolite that prevents immature WBCs from maturing; it occurs in approximately 15% to 20% of patients with AML[Stein 2014]

Action required